The Effectiveness of Remdesivir versus Ruxolitinib as Covid-19 Supportive Management: Systematic Review, Meta-Analysis

DOI

10.2991/ahsr.k.210115.114How to use a DOI?

Keywords

Covid-19, Remdesivir, Ruxolitinib, Systemic Review, Meta-Analysis

Abstract

The treatment regimen in severe Covid-19 patients has several types of therapies. However, there is uncertainty about which therapies are more effective in the covid-19 weight category. In June 2020, the study was conducted with keyword search [REMDESIVIR] [RUXOLITINIB] [COVID19] in 2010-2020 using PUBMED.gov. This study used rct (randomization controller trial) method with the theme: the comparison of the effectiveness use of Remdesivir with Ruxolitinib on Covid-19. From the results of the analysis using forest plot obtained, there was a significant difference in the administration of Remdesivir therapy with Ruxolitinib on the improvement from covid-19 on day 7 (1.26 CI 95% 0.41 to 3.86) and day 14 (RR 1.26 CI 95% 0.41 to 3.86). Ruxolitinib therapy is more effective than Remdesivir applied for Covid-19 patients.

Copyright

© 2021, the Authors. Published by Atlantis Press.

Open Access

This is an open access article distributed under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).

Download article (PDF)

TY  - CONF
AU  - Nuriyatul Fhatonah
AU  - Ma’sum
AU  - Zenith Putri Dewianti
AU  - Nur’aini
AU  - Nita Rusdiana
PY  - 2021
DA  - 2021/01/16
TI  - The Effectiveness of Remdesivir versus Ruxolitinib as Covid-19 Supportive Management: Systematic Review, Meta-Analysis
BT  - Proceedings of the 4th International Conference on Sustainable Innovation 2020–Health Science and Nursing (ICoSIHSN 2020)
PB  - Atlantis Press
SP  - 604
EP  - 607
SN  - 2468-5739
UR  - https://doi.org/10.2991/ahsr.k.210115.114
DO  - 10.2991/ahsr.k.210115.114
ID  - Fhatonah2021
ER  -